Analysts think CRMD stock price could increase by 170%
Jul 31, 2024, 6:25 AM
33.89%
What does CRMD do
CorMedix, Inc., based in Berkeley Heights, New Jersey, specializes in developing and commercializing products like DefenCath, a solution to prevent infections in patients with central venous catheters. Founded in 2010, the company employs 40 people and explores taurolidine's potential in treating rare pediatric tumors.
6 analysts think CRMD stock price will increase by 170.20%. The current median analyst target is $12.24 compared to a current stock price of $4.53. The lowest analysts target is $9.09 and the highest analyst target is $19.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
